Unknown

Dataset Information

0

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.


ABSTRACT:

Background

Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib.

Methods

Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A DLT was defined as any toxicity leading to dose reduction or treatment discontinuation. Body composition was evaluated using CT scan obtained within 1 month before treatment initiation.

Results

Among 61 patients eligible for analysis, 52.5% were sarcopenic and 32.8% had both sarcopenia and a body mass index (BMI)<25?kg?m(-2). Eighteen patients (29.5%) experienced a DLT during the first cycle. Sarcopenic patients with a BMI<25?kg?m(-2) experienced more DLTs (P=0.01; odds ratio=4.1; 95% CI: (1.3-13.3)), more cumulative grade 2 or 3 toxicities (P=0.008), more grade 3 toxicities (P=0.04) and more acute vascular toxicities (P=0.009).

Conclusion

Patients with sarcopenia and a BMI<25?kg?m(-2) experienced significantly more DLTs during the first cycle of treatment.

SUBMITTER: Huillard O 

PROVIDER: S-EPMC3619075 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.

Huillard O O   Mir O O   Peyromaure M M   Tlemsani C C   Giroux J J   Boudou-Rouquette P P   Ropert S S   Delongchamps N Barry NB   Zerbib M M   Goldwasser F F  

British journal of cancer 20130305 5


<h4>Background</h4>Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib.<h4>Methods</h4>Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A  ...[more]

Similar Datasets

| S-EPMC3364283 | biostudies-literature
| S-EPMC6711417 | biostudies-literature
| S-EPMC4038335 | biostudies-literature
| S-EPMC3228204 | biostudies-literature
| S-EPMC7083394 | biostudies-literature
| S-EPMC5065111 | biostudies-literature
| S-EPMC3466395 | biostudies-literature
| S-EPMC5710345 | biostudies-literature
| S-EPMC8277084 | biostudies-literature
| S-EPMC9697051 | biostudies-literature